Keros Therapeutics Began Phase 2 Duchenne Trial
The company has dosed the first patient in an open-label study evaluating rinvatercept for Duchenne muscular dystrophy.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Are pharmaceutical companies doing enough to develop and provide treatment options for rare diseases?
Keros Therapeutics has officially initiated a Phase 2 clinical trial for its drug candidate rinvatercept. The study aims to evaluate the treatment in patients suffering from Duchenne muscular dystrophy.
Why it matters
The trial explores a new approach to managing Duchenne muscular dystrophy by using rinvatercept as a ligand trap to inhibit myostatin and activin A. This mechanism is intended to address the underlying progression of the condition in both late-ambulatory and early non-ambulatory patients.
The study, registered under NCT07704099, is an open-label, multi-cohort basket trial. It is specifically designed to assess safety, tolerability, pharmacokinetics, and the presence of anti-drug antibodies in participants.
The players
Keros Therapeutics
This is a biopharmaceutical company based in Lexington, Massachusetts, that focuses on developing novel treatments for patients with hematologic and musculoskeletal disorders.
The details
The research program, led by the Lexington, Massachusetts-based company, focuses on measurable improvements across skeletal muscle, motor, cardiac, and pulmonary health indicators. Researchers will monitor patients to determine if the ligand trap effectively slows or alters the progression of Duchenne muscular dystrophy.
Timeline
September 28, 2026: The first patient was dosed in the Phase 2 clinical trial.
First half of 2027: Keros Therapeutics expects to release initial trial data.
The Tech Race
This clinical trial represents a broader industry pivot toward using ligand traps to specifically modulate muscle-growth pathways. It follows a pattern set by previous attempts to address muscular dystrophy by targeting myostatin and activin A to preserve function.
This trial marks a step toward potential new treatment options for families and patients currently managing the progression of Duchenne muscular dystrophy. Participants and their care teams will benefit from ongoing monitoring of pharmacokinetics and functional health indicators throughout the study period.
The takeaway
The initiation of this study highlights the ongoing scientific effort to find precision treatments for rare genetic muscle conditions. Continued observation of this trial may clarify whether ligand trap technology can offer functional improvements for patients with limited mobility.
What happens next
Keros Therapeutics expects to release initial data from the clinical trial in the first half of 2027.
Further reading
Learn more about the latest industry research in the Biotech section.
Live Poll
Are pharmaceutical companies doing enough to develop and provide treatment options for rare diseases?
